PortfoliosLab logoPortfoliosLab logo
ISIN
US46266A1097
CUSIP
46266A109
IPO Date
Jul 16, 2014

Highlights

Market Cap
$1.18B
Enterprise Value
$1.12B
EPS (TTM)
$1.84
PE Ratio
49.94
PEG Ratio
2.09
Total Revenue (TTM)
$86.28M
Gross Profit (TTM)
$66.30M
EBITDA (TTM)
$30.55M
Year Range
$55.11 - $107.90
Target Price
$120.00
ROA (TTM)
20.64%
ROE (TTM)
23.97%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


IRadimed Corporation

Performance

IRMD Performance Chart

IRadimed Corporation (IRMD) is down 5.4% since the beginning of the year. At $92 per share, IRMD is trading 15.0% below its 52-week high of $108. Investors who bought $1,000 worth of IRMD shares 5 years ago would now be looking at an investment worth $3,590.


Loading charts...

S&P 500 Index

Returns By Period

IRadimed Corporation (IRMD) has returned -5.35% so far this year and 59.63% over the past 12 months. Looking at the last ten years, IRMD has achieved an annualized return of 17.17%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.


IRadimed Corporation

1D
-0.55%
1M
-0.45%
YTD
-5.35%
6M
-5.20%
1Y
59.63%
3Y*
26.44%
5Y*
29.13%
10Y*
17.17%

Benchmark (S&P 500 Index)

1D
-0.37%
1M
-0.01%
YTD
9.16%
6M
8.64%
1Y
25.22%
3Y*
19.78%
5Y*
11.99%
10Y*
13.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

IRMD Monthly Returns History

Based on dividend-adjusted daily data since Jul 16, 2014, IRMD's average daily return is +0.13%, while the average monthly return is +2.57%. At this rate, an investment would double in approximately 2.3 years.

Historically, 60% of months were positive and 40% were negative. The best month was Oct 2017 with a return of +48.4%, while the worst month was Oct 2016 at -44.4%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 4 months.

On a daily basis, IRMD closed higher 50% of trading days. The best single day was Jul 30, 2019 with a return of +33.3%, while the worst single day was Oct 4, 2016 at -36.7%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20260.62%5.98%-7.02%-13.32%8.90%1.14%-5.35%
20257.65%-8.68%-2.65%-0.13%10.78%3.30%-2.43%24.47%-1.77%7.94%21.61%4.90%79.69%
2024-12.77%1.35%4.81%-7.68%4.95%3.46%6.30%0.88%7.09%-2.03%9.76%1.98%16.99%
202332.20%4.61%3.66%5.79%12.97%1.51%-7.98%5.24%-4.02%-8.18%7.85%9.55%75.37%
2022-13.83%27.36%-9.78%-26.61%-0.67%3.82%24.48%-20.59%-10.40%-3.36%1.76%-4.30%-37.53%
20218.51%-9.86%15.56%7.45%0.43%5.75%14.45%0.30%-0.50%11.10%20.58%2.69%102.68%

Benchmark Metrics

IRadimed Corporation has an annualized alpha of 24.42%, beta of 0.82, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since July 16, 2014.

  • This stock captured 172.78% of S&P 500 Index gains and 128.84% of its losses - amplifying both gains and losses, but participating more in upside than downside.
  • R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
24.42%
Beta
0.82
0.08
Upside Capture
172.78%
Downside Capture
128.84%

Return for Risk

Risk / Return Rank

IRMD ranks 84 for risk / return — in the top 84% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.


IRMD Risk / Return Rank: 8484
Overall Rank
IRMD Sharpe Ratio Rank: 8686
Sharpe Ratio Rank
IRMD Sortino Ratio Rank: 8585
Sortino Ratio Rank
IRMD Omega Ratio Rank: 8383
Omega Ratio Rank
IRMD Calmar Ratio Rank: 8383
Calmar Ratio Rank
IRMD Martin Ratio Rank: 8484
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for IRadimed Corporation (IRMD) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


IRMDBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-0.26

Sortino ratioReturn per unit of downside risk

-0.09

Omega ratioGain probability vs. loss probability

1.33

1.37

-0.04

Calmar ratioReturn relative to maximum drawdown

2.91

2.78

+0.12

Martin ratioReturn relative to average drawdown

8.03

12.44

-4.41

Dividends

Dividend History

IRadimed Corporation provided a 1.35% dividend yield over the last twelve months, with an annual payout of $1.24 per share.


1.00%1.50%2.00%2.50%3.00%3.50%$0.00$0.50$1.00$1.502022202320242025
Dividends
Dividend Yield
PeriodTTM2025202420232022
Dividend$1.24$1.18$0.45$1.68$1.00

Dividend yield

1.35%1.21%0.82%3.54%3.53%

Monthly Dividends

The table displays the monthly dividend distributions for IRadimed Corporation. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.00$0.20$0.00$0.00$0.20$0.00$0.40
2025$0.00$0.17$0.00$0.00$0.17$0.00$0.00$0.17$0.00$0.00$0.17$0.50$1.18
2024$0.00$0.00$0.00$0.00$0.15$0.00$0.00$0.15$0.00$0.00$0.15$0.00$0.45
2023$0.00$1.05$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.63$1.68
2022$1.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$1.00

Dividend Yield & Payout


Dividend Yield

IRadimed Corporation has a dividend yield of 1.35%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.

Payout Ratio

IRadimed Corporation has a payout ratio of 65.37%, which is quite average when compared to the overall market. This suggests that IRadimed Corporation strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the IRadimed Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the IRadimed Corporation was 75.83%, occurring on Apr 5, 2017. Recovery took 369 trading sessions.

The current IRadimed Corporation drawdown is 12.57%.


Related event

Drawdown

Fall

Recovery

Underwater

2017 bear market2017
-75.83%Apr 2017
1y 4mo1y 5mo
2y 10moNov 2015 - Sep 2018
COVID crash2020
-56.72%Mar 2020
1y 5mo1y 3mo
2y 9moOct 2018 - Jul 2021
Bear market2022
-49.38%Oct 2022
6mo 18d2y 4d
2y 6moMar 2022 - Oct 2024
2014 bear market2014
-40.21%Sep 2014
28d3mo 4d
4mo 2dAug 2014 - Dec 2014
Bear market2022
-27.28%Jan 2022
22d12d
1mo 4dJan 2022 - Feb 2022

Drawdown Indicators


IRMDBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-75.83%

-56.78%

-19.05%

Max Drawdown (1Y)

Largest decline over 1 year

-20.62%

-9.10%

-11.52%

Max Drawdown (3Y)

Largest decline over 3 years

-25.83%

-18.90%

-6.93%

Max Drawdown (5Y)

Largest decline over 5 years

-49.38%

-25.43%

-23.95%

Max Drawdown (10Y)

Largest decline over 10 years

-64.30%

-33.92%

-30.38%

Current Drawdown

Current decline from peak

-12.57%

-1.80%

-10.77%

Average Drawdown

Average peak-to-trough decline

-28.01%

-10.71%

-17.30%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.45%

2.03%

+5.42%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of IRadimed Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how IRadimed Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for IRMD, comparing it with other companies in the Medical Devices industry. Currently, IRMD has a P/E ratio of 49.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for IRMD compared to other companies in the Medical Devices industry. IRMD currently has a PEG ratio of 2.1. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for IRMD relative to other companies in the Medical Devices industry. Currently, IRMD has a P/S ratio of 13.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for IRMD in comparison with other companies in the Medical Devices industry. Currently, IRMD has a P/B value of 12.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with IRMD

Add IRadimed Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with IRMD